Northwest Biotherapeutics, Inc. (BST:NBYB)
Germany
· Delayed Price · Currency is EUR 0.1840
-0.0010 (-0.54%)
At close: Dec 5, 2025
Northwest Biotherapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Cash & Equivalents | 4.56 | 2.18 | 2.13 | 6.97 | 15.17 | 9.98 | Upgrade
|
| Cash & Short-Term Investments | 4.56 | 2.18 | 2.13 | 6.97 | 15.17 | 9.98 | Upgrade
|
| Cash Growth | 55.16% | 2.31% | -69.48% | -54.08% | 51.95% | 2583.60% | Upgrade
|
| Prepaid Expenses | 2.33 | 1.89 | 2 | 2.46 | 2.12 | 5.53 | Upgrade
|
| Total Current Assets | 7.2 | 4.06 | 4.13 | 9.43 | 17.29 | 15.51 | Upgrade
|
| Property, Plant & Equipment | 21.14 | 20.38 | 21.46 | 19.64 | 19.92 | 14.6 | Upgrade
|
| Goodwill | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | 0.63 | Upgrade
|
| Other Intangible Assets | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 | 1.29 | Upgrade
|
| Other Long-Term Assets | 0.36 | 0.37 | 0.36 | 0.35 | 1.04 | 0.87 | Upgrade
|
| Total Assets | 30.61 | 26.73 | 27.87 | 31.32 | 40.16 | 32.9 | Upgrade
|
| Accounts Payable | 26.88 | 16.97 | 10.24 | 10.69 | 6.98 | 12.74 | Upgrade
|
| Short-Term Debt | 13.57 | 14.19 | 3.94 | 15.4 | 7.1 | 6.13 | Upgrade
|
| Current Portion of Long-Term Debt | 26.83 | 20.19 | 16.54 | 0.14 | 0.14 | 0.14 | Upgrade
|
| Current Portion of Leases | 0.4 | 0.33 | 0.31 | 0.35 | 0.32 | 0.17 | Upgrade
|
| Other Current Liabilities | 20.24 | 16.6 | 14.17 | 99.43 | 119.24 | 363.25 | Upgrade
|
| Total Current Liabilities | 87.91 | 68.27 | 45.2 | 126.01 | 133.77 | 382.42 | Upgrade
|
| Long-Term Debt | 31.81 | 28.3 | 20.31 | 5.99 | 25.16 | 8.51 | Upgrade
|
| Long-Term Leases | 4.45 | 4.44 | 4.45 | 4.37 | 5.23 | 4.92 | Upgrade
|
| Other Long-Term Liabilities | 1.7 | 4.7 | 4.95 | - | - | - | Upgrade
|
| Total Liabilities | 125.86 | 105.71 | 74.92 | 136.37 | 164.15 | 395.85 | Upgrade
|
| Common Stock | 1.52 | 1.33 | 1.18 | 1.07 | 0.95 | 0.83 | Upgrade
|
| Additional Paid-In Capital | 1,396 | 1,345 | 1,291 | 1,165 | 1,067 | 1,009 | Upgrade
|
| Retained Earnings | -1,505 | -1,443 | -1,360 | -1,297 | -1,192 | -1,371 | Upgrade
|
| Comprehensive Income & Other | -1.3 | 2.96 | 1.46 | 3.07 | 0.28 | -1.23 | Upgrade
|
| Total Common Equity | -108.65 | -94.49 | -65.77 | -128.1 | -123.99 | -362.95 | Upgrade
|
| Shareholders' Equity | -95.25 | -78.98 | -47.06 | -105.04 | -123.99 | -362.95 | Upgrade
|
| Total Liabilities & Equity | 30.61 | 26.73 | 27.87 | 31.32 | 40.16 | 32.9 | Upgrade
|
| Total Debt | 77.05 | 67.44 | 45.56 | 26.25 | 37.94 | 19.86 | Upgrade
|
| Net Cash (Debt) | -72.49 | -65.27 | -43.43 | -19.29 | -22.77 | -9.87 | Upgrade
|
| Net Cash Per Share | -0.05 | -0.05 | -0.04 | -0.02 | -0.02 | -0.01 | Upgrade
|
| Filing Date Shares Outstanding | 1,541 | 1,391 | 1,190 | 1,073 | 960.02 | 842.14 | Upgrade
|
| Total Common Shares Outstanding | 1,518 | 1,329 | 1,176 | 1,068 | 948.45 | 829.63 | Upgrade
|
| Working Capital | -80.71 | -64.21 | -41.08 | -116.58 | -116.48 | -366.91 | Upgrade
|
| Book Value Per Share | -0.07 | -0.07 | -0.06 | -0.12 | -0.13 | -0.44 | Upgrade
|
| Tangible Book Value | -110.57 | -96.41 | -67.69 | -130.02 | -125.91 | -364.87 | Upgrade
|
| Tangible Book Value Per Share | -0.07 | -0.07 | -0.06 | -0.12 | -0.13 | -0.44 | Upgrade
|
| Land | 0.09 | 0.09 | 0.09 | 0.08 | 0.09 | 0.09 | Upgrade
|
| Machinery | 4.98 | 3.69 | 3.26 | 2.54 | 2.11 | 1.62 | Upgrade
|
| Construction In Progress | - | - | - | 2.03 | - | 9.07 | Upgrade
|
| Leasehold Improvements | 18.9 | 17.97 | 17.79 | 13.07 | 13.91 | 0.08 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.